These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18756940)

  • 61. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
    Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
    J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
    Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
    Niikura N; Liu J; Hayashi N; Palla SL; Tokuda Y; Hortobagyi GN; Ueno NT; Theriault RL
    Cancer; 2012 Apr; 118(8):2039-47. PubMed ID: 22139648
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
    Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
    Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Recommendations for zoledronic acid treatment of patients with bone metastases.
    Berenson JR
    Oncologist; 2005 Jan; 10(1):52-62. PubMed ID: 15632252
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study.
    Armingeat T; Brondino R; Pham T; Legré V; Lafforgue P
    Osteoporos Int; 2006; 17(11):1659-65. PubMed ID: 16896508
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.
    Diel IJ; Weide R; Köppler H; Antràs L; Smith M; Green J; Wintfeld N; Neary M; Duh MS
    Support Care Cancer; 2009 Jun; 17(6):719-25. PubMed ID: 19089462
    [TBL] [Abstract][Full Text] [Related]  

  • 69. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Loading dose ibandronate versus standard oral ibandronate in patients with bone metastases from breast cancer.
    Macpherson IR; Bray C; Hopkins C; Hannon RA; Lewsley LA; Ritchie DM; Canney P
    Clin Breast Cancer; 2015 Apr; 15(2):117-27. PubMed ID: 25454689
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Decreases in pain at rest and movement-related pain during zoledronic acid treatment in patients with bone metastases due to breast or prostate cancer: a pilot study.
    Ripamonti C; Fagnoni E; Campa T; Giardina V; Brunelli C; Pigni A; De Conno F
    Support Care Cancer; 2007 Oct; 15(10):1177-84. PubMed ID: 17333295
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.
    Chen F; Dai Z; Kang Y; Lv G; Keller ET; Jiang Y
    Osteoporos Int; 2016 Apr; 27(4):1469-1476. PubMed ID: 26556733
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.
    Sabry NA; Habib EE
    Med Oncol; 2011 Jun; 28(2):584-90. PubMed ID: 20204542
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y; Zeng JC; Yin F; Zhang CL; Zhang Y; Li SX; Liu X; Zhang C; Xue QY; Lin H; Pei FX
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
    Sanfilippo KM; Gage B; Luo S; Weilbaecher K; Tomasson M; Vij R; Colditz G; Carson K
    Leuk Lymphoma; 2015 Mar; 56(3):615-21. PubMed ID: 24844358
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    Francini F; Pascucci A; Bargagli G; Francini E; Conca R; Miano ST; Martellucci I; Migali C; Gotti G; Fiaschi AI; Cozzolino A; Petrioli R
    Int J Clin Oncol; 2011 Jun; 16(3):264-9. PubMed ID: 21240683
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Effectiveness and tolerability of zoledronic acid in the treatment of metastatic prostate cancer].
    Cózar Olmo JM; Carballido Rodriguez J; Luque Galvez P; Tabernero Gómez AG; Barreiro Mouro A; Sánchez Sánchez E; González Enguita C; Alcover García J; Garcia-Galisteo E; Abascal García JM; Sanchez Chapado M; GómezVeiga F; Minguez Martínez RJ; Rodriguez Antolin A; Medina López RA; Rico Morales M; Regadera Sejas FJ; Búcar Terrades S; Jamardo Gonzalez D; Gálvez R
    Actas Urol Esp; 2008 May; 32(5):492-501. PubMed ID: 18604999
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
    Iyer SP; Beck JT; Stewart AK; Shah J; Kelly KR; Isaacs R; Bilic S; Sen S; Munshi NC
    Br J Haematol; 2014 Nov; 167(3):366-75. PubMed ID: 25139740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.